Medicine and Dentistry
Magnetic Resonance Imaging
100%
Biopsy
97%
Prostate Cancer
48%
Prostatectomy
41%
Glycon
41%
Phase II Trials
41%
Neuroendocrine Tumor
41%
Prostate Biopsy
31%
Malignant Neoplasm
26%
Cancer Diagnosis
25%
Prostate Specific Antigen
20%
Colorectal Cancer
20%
Oncology
20%
Gleason Score
20%
Prostate Hypertrophy
20%
Progression Free Survival
20%
Surgical Margin
20%
Whole Body MRI
20%
Norfloxacin
20%
Liver Metastasis
20%
4 Iodo 2,5 Dimethoxyamphetamine
20%
Diffusion MRI
20%
Retrospective Study
19%
Surgery
17%
Multiparametric Magnetic Resonance Imaging
16%
Neoplasm
16%
Fluorouracil
13%
Oxaliplatin
13%
Folinic Acid
13%
Disease
13%
Surgeon
12%
Imaging Technique
12%
Overall Survival
10%
Health Care Cost
10%
Odds Ratio
8%
Biochemical Recurrence
8%
Glycemic
6%
Radioisotope
6%
Nuclear Magnetic Resonance
6%
Sensitivity and Specificity
6%
Abdominal Radiology
6%
Nuclear Medicine
6%
Monotherapy
6%
Hazard Ratio
6%
Logistic Regression Analysis
6%
Diagnosis
5%
Prostate Cancer Diagnosis
5%
Keyphrases
Multiparametric MRI (mpMRI)
41%
Radical Prostatectomy
41%
Targeted Biopsy
32%
Grade Group
31%
Radiologists
29%
Data Systems
25%
Prostate Imaging Reporting
25%
Benign Prostatic Hyperplasia
20%
Conversion Chemotherapy
20%
Reporting System
20%
Fusion Prostate Biopsy
20%
Interobserver Agreement
20%
Colorectal Liver Metastases
20%
Recent Advances
20%
Metformin
20%
Gleason Grade Group
20%
Unresectable Liver Metastases
20%
Nodule
20%
Well-differentiated Neuroendocrine Tumor
20%
Phase II Trial
20%
Resource-limited Settings
20%
Surgical Margin
20%
Structured Report
20%
Restricted Diffusion
20%
Multiparametric Prostate MRI
20%
Oncology Setting
20%
Transition Zone
20%
Histological Analysis
20%
Flox
20%
Whole-body Magnetic Resonance Imaging
20%
PI-RADS
20%
Experience Level
20%
Clinically Significant Prostate Cancer
20%
Positive Surgical Margin
16%
Peripheral Zone
15%
Leucovorin
13%
Fluorouracil
13%
Oxaliplatin
13%
Prostate-specific Antigen
12%
Positivity Rate
10%
Lesion Size
9%
Prostate Lesions
8%
Confidence Interval
8%
Adjusted Odds Ratio
8%
Prostate-specific Antigen Density
8%
Surgeons
8%
Propensity Score
8%
Biochemical Recurrence
8%
Chemotherapy
6%
Oncology
6%